Which medications in the drug class Monoclonal Antibodies, Endocrine are used in the treatment of Hypophosphatemic Rickets?

Updated: May 18, 2020
  • Author: James CM Chan, MD; Chief Editor: Sasigarn A Bowden, MD  more...
  • Print

Monoclonal Antibodies, Endocrine

The first targeted therapy directed toward correcting renal phosphate wasting, an underlying etiology of X-linked hypophosphatemia (XLH), has been approved in the United States.

Burosumab (Burosumab-twza, Crysvita)

Recombinant fully human monoclonal IgG1 antibody that binds fibroblast growth factor 23 (FGF23). This binding inhibits the biological activity of FGF23, thereby restoring renal phosphate reabsorption and increasing the serum concentration of 1,25 dihydroxy vitamin D. Burosumab is indicated for XLH in adults and children aged 1 year or older.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!